Targeted Modalities Denileukin diftitox Ontak

Denileukin diftitox (IL-2 receptor specific fusion protein combined with diphtheria toxin) targets selectively the IL-2 receptor on malignant and activated T cells. In phase I/II and III trials it showed favorable 3074 to 37%75 response rates in CTCL patients. These trials were limited to patients with CD25 expression (alpha chain of IL-2R) in more than 20% of malignant T cells. The quality of life in responding patients was significantly improved.76 However, adverse effects including acute transfusion-related events such as fever, rash, chills, myalgias, and vascular leak syndrome (VLS) have been reported. VLS occurred in 27% of the patients, which may be diminished by premedication with steroids.77

0 0

Post a comment